nach oben

Erschienen in:

01.01.2010 | Original paper

Plasma enterolactone and risk of colon and rectal cancer in a case–cohort study of Danish men and women

verfasst von: Nina Føns Johnsen, Anja Olsen, Birthe Lykke Riegels Thomsen, Jane Christensen, Rikke Egeberg, Knud Erik Bach Knudsen, Steffen Loft, Kim Overvad, Anne Tjønneland

Erschienen in: Cancer Causes & Control | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

This case–cohort study examined the association between plasma enterolactone concentration and incidence of colon and rectal cancer in the Diet, Cancer and Health cohort, which enrolled 57,053 participants aged 50–64. Information about diet and lifestyle was obtained by questionnaire, and data on prescriptions of antibiotics were obtained from the Danish Prescription Registry. Cases diagnosed during 5.9 years of follow-up and a randomly selected sample of the cohort had a plasma sample analyzed for enterolactone by time-resolved fluoro-immuno assay. Associations were analyzed by Cox proportional hazards model. A total of 244 colon cancer cases, 137 rectal cancer cases, and 370 sub-cohort members were included in the statistical analyses. For each doubling in enterolactone concentration, we found lower risk of colon cancer among women [IRR (95% CI) = 0.76 (0.60–0.96)] and a tendency toward lower risk of rectal cancer [IRR (95% CI) = 0.83 (0.60–1.14)]. Among men, a doubling in enterolactone tended to be associated with higher risk of colon cancer [IRR (95% CI) = 1.09 (0.89–1.34)] and was associated with statistically significantly higher risk of rectal cancer [IRR (95% CI) = 1.74 (1.25–2.44)]. Exclusion of antibiotics users strengthened the results slightly. In conclusion, with higher enterolactone levels, we found lower risk of colon cancer among women and higher risk of rectal cancer among men.

Saarinen NM, Smeds A, Makela SI et al (2002) Structural determinants of plant lignans for the formation of enterolactone in vivo. J Chromatogr B Analyt Technol Biomed Life Sci 777:311–319CrossRefPubMed

Mazur W (1998) Phytoestrogen content in foods. Baillieres Clin Endocrinol Metab 12:729–742CrossRefPubMed

Mazur W, Adlercreutz H (1998) Natural and anthropogenic environmental oestrogens: the scientific basis for risk assessment. Pure Appl Chem 70:1759–1776CrossRef

Axelson M, Setchell KD (1981) The excretion of lignans in rats—evidence for an intestinal bacterial source for this new group of compounds. FEBS Lett 123:337–342CrossRefPubMed

Stitch SR, Toumba JK, Groen MB et al (1980) Excretion, isolation and structure of a new phenolic constituent of female urine. Nature 287:738–740CrossRefPubMed

Nesbitt PD, Lam Y, Thompson LU (1999) Human metabolism of mammalian lignan precursors in raw and processed flaxseed. Am J Clin Nutr 69:549–555PubMed

Rowland IR, Wiseman H, Sanders TA, Adlercreutz H, Bowey EA (2000) Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr Cancer 36:27–32CrossRefPubMed

Adlercreutz H (2002) Phyto-oestrogens and cancer. Lancet Oncol 3:364–373CrossRefPubMed

Kilkkinen A, Pietinen P, Klaukka T, Virtamo J, Korhonen P, Adlercreutz H (2002) Use of oral antimicrobials decreases serum enterolactone concentration. Am J Epidemiol 155:472–477CrossRefPubMed

10.

Setchell KD, Lawson AM, Mitchell FL, Adlercreutz H, Kirk DN, Axelson M (1980) Lignans in man and in animal species. Nature 287:740–742CrossRefPubMed

11.

Adlercretutz H, Heikkinen R, Woods M, Fotsis T, Dwyer JT, Goldin BR (1982) Excretion of the lignans enterolactone and enterodiol and of equol in omnivorous and vegetarian postmenopausal women and in women with breast cancer. Lancet 11:1295–1298CrossRef

12.

Mueller SO, Simon S, Chae K, Metzler M, Korach KS (2004) Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 80:14–25CrossRefPubMed

13.

Penttinen P, Jaehrling J, Damdimopoulos AE et al (2007) Diet-derived polyphenol metabolite enterolactone is a tissue-specific estrogen receptor activator. Endocrinology 148:4875–4886CrossRefPubMed

14.

Kitts DD, Yuan YV, Wijewickreme AN, Thompson LU (1999) Antioxidant activity of the flaxseed lignan secoisolariciresinol diglucoside and its mammalian lignan metabolites enterodiol and enterolactone. Moll Cell Biochem 202:91–100CrossRef

15.

Niemeyer HB, Metzler M (2003) Differences in the antioxidant capacity of plant and mammalian lignans. J Food Eng 56:255–256CrossRef

16.

Prasad K (2000) Antioxidant activity of secoisolariciresinol diglucoside-derived metabolites, secoisolariciresinol, enterodiol, and enterolactone. Int J Angiol 9:220–225CrossRefPubMed

17.

Danbara N, Yuri T, Tsujita-Kyutoku M, Tsukamoto R, Uehara N, Tsubura A (2005) Enterolactone induces apoptosis and inhibits growth of Colo 201 human colon cancer cells both in vitro and in vivo. Anticancer Res 25:2269–2276PubMed

18.

Mousavi Y, Adlercreutz H (1992) Enterolactone and estradiol inhibit each other’s proliferative effect on MCF-7 breast cancer cells in culture. J Steroid Biochem Mol Biol 41:615–619CrossRefPubMed

19.

Brooks JD, Thompson LU (2005) Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol 94:461–467CrossRefPubMed

20.

Sung MK, Lautens M, Thompson LU (1998) Mammalian lignans inhibit the growth of estrogen-independent human colon tumor cells. Anticancer Res 18:1405–1408PubMed

21.

Konstantinopoulos PA, Kominea A, Vandoros G et al (2003) Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. Eur J Cancer 39:1251–1258CrossRefPubMed

22.

Wada-Hiraike O, Warner M, Gustafsson JA (2006) New developments in oestrogen signalling in colonic epithelium. Biochem Soc Trans 34:1114–1116CrossRefPubMed

23.

Castiglione F, Taddei A, Degl’Innocenti DR et al (2008) Expression of estrogen receptor beta in colon cancer progression. Diagn Mol Pathol 17:231–236CrossRefPubMed

24.

Jassam N, Bell SM, Speirs V, Quirke P (2005) Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes’ staging. Oncol Rep 14:17–21PubMed

25.

Xie LQ, Yu JP, Luo HS (2004) Expression of estrogen receptor beta in human colorectal cancer. World J Gastroenterol 10:214–217PubMed

26.

Hebert-Croteau N (1998) A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev 7:653–659PubMed

27.

Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD (2002) Postmenopausal hormone replacement therapy: scientific review. JAMA 288:872–881CrossRefPubMed

28.

Kuijsten A, Hollman PC, Boshuizen HC et al (2008) Plasma enterolignan concentrations and colorectal cancer risk in a nested case–control study. Am J Epidemiol 167:734–742CrossRefPubMed

29.

Ward H, Chapelais G, Kuhnle GG, Luben R, Khaw KT, Bingham S (2008) Lack of prospective associations between plasma and urinary phytoestrogens and risk of prostate or colorectal cancer in the European Prospective into Cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev 17:2891–2894CrossRefPubMed

30.

Tjonneland A, Olsen A, Boll K et al (2007) Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark. Scand J Public Health 35:432–441CrossRefPubMed

31.

Overvad K, Tjonneland A, Haraldsdottir J, Ewertz M, Jensen OM (1991) Development of a semiquantitative food frequency questionnaire to assess food, energy and nutrient intake in Denmark. Int J Epidemiol 20:900–905CrossRefPubMed

32.

Tjonneland A, Overvad K, Haraldsdottir J, Bang S, Ewertz M, Jensen OM (1991) Validation of a semiquantitative food frequency questionnaire developed in Denmark. Int J Epidemiol 20:906–912CrossRefPubMed

33.

Tjonneland A, Haraldsdottir J, Overvad K, Stripp C, Ewertz M, Jensen OM (1992) Influence of individually estimated portion size data on the validity of a semiquantitative food frequency questionnaire. Int J Epidemiol 21:770–777CrossRefPubMed

34.

Lauritsen J (1998) Foodcalc 1.3

35.

Probert CJ, Emmett PM, Heaton KW (1993) Intestinal transit time in the population calculated from self made observations of defecation. J Epidemiol Community Health 47:331–333CrossRefPubMed

36.

Gaist D, Sorensen HT, Hallas J (1997) The Danish prescription registries. Dan Med Bull 44:445–448PubMed

37.

Adlercreutz H, Wang GJ, Lapcik O et al (1998) Time-resolved fluoroimmunoassay for plasma enterolactone. Anal Biochem 265:208–215CrossRefPubMed

38.

Stumpf K, Uehara M, Nurmi T, Adlercreutz H (2000) Changes in the time-resolved fluoroimmunoassay of plasma enterolactone. Anal Biochem 284:153–157CrossRefPubMed

39.

Prentice RL (1986) A case–cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73:1–11CrossRef

40.

Barlow WE, Ichikawa L, Rosner D, Izumi S (1999) Analysis of case–cohort designs. J Clin Epidemiol 52:1165–1172CrossRefPubMed

41.

Lin DY, Wei LJ (1989) The robust inference for the cox proportional hazards model. J Am Stat Assoc 84:1074–1078CrossRef

42.

Johnsen NF, Hausner H, Olsen A et al (2004) Intake of whole grains and vegetables determines the plasma enterolactone concentration of Danish women. J Nutr 134:2691–2697PubMed

43.

Johnsen NF, Christensen J, Thomsen BL et al (2006) Physical activity and risk of colon cancer in a cohort of Danish middle-aged men and women. Eur J Epidemiol 21:877–884CrossRefPubMed

44.

Horner NK, Kristal AR, Prunty J, Skor HE, Potter JD, Lampe JW (2002) Dietary determinants of plasma enterolactone. Cancer Epidemiol Biomarkers Prev 11:121–126PubMed

45.

Hulten K, Winkvist A, Lenner P, Johansson R, Adlercreutz H, Hallmans G (2002) An incident case-referent study on plasma enterolactone and breast cancer risk. Eur J Nutr 41:168–176CrossRefPubMed

46.

Kilkkinen A, Stumpf K, Pietinen P, Valsta LM, Tapanainen H, Adlercreutz H (2001) Determinants of serum enterolactone concentration. Am J Clin Nutr 73:1094–1100PubMed

47.

Lampe JW, Gustafson DR, Hutchins AM et al (1999) Urinary isoflavonoid and lignan excretion on a Western diet: relation to soy, vegetable, and fruit intake. Cancer Epidemiol Biomarkers Prev 8:699–707PubMed

48.

Milder IE, Kuijsten A, Arts IC et al (2007) Relation between plasma enterodiol and enterolactone and dietary intake of lignans in a Dutch endoscopy-based population. J Nutr 137:1266–1271PubMed

49.

Sonestedt E, Borgquist S, Ericson U et al (2008) Enterolactone is differently associated with estrogen receptor beta-negative and -positive breast cancer in a Swedish nested case–control study. Cancer Epidemiol Biomarkers Prev 17:3241–3251CrossRefPubMed

50.

Vanharanta M, Mursu J, Nurmi T et al (2002) Phloem fortification in rye bread elevates serum enterolactone level. Eur J Clin Nutr 56:952–957CrossRefPubMed

51.

Kuijsten A, Arts IC, Hollman PC, van’t Veer P, Kampman E (2006) Plasma enterolignans are associated with lower colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 15:1132–1136CrossRefPubMed

52.

Carreau C, Flouriot G, netau-Pelissero C, Potier M (2008) Enterodiol and enterolactone, two major diet-derived polyphenol metabolites have different impact on ERalpha transcriptional activation in human breast cancer cells. J Steroid Biochem Mol Biol 110:176–185CrossRefPubMed

53.

Martin ME, Haourigui M, Pelissero C, Benassayag C, Nunez EA (1996) Interactions between phytoestrogens and human sex steroid binding protein. Life Sci 58:429–436CrossRefPubMed

54.

Schottner M, Gansser D, Spiteller G (1997) Lignans from the roots of Urtica dioica and their metabolites bind to human sex hormone binding globulin (SHBG). Planta Med 63:529–532CrossRefPubMed

55.

Hausner H, Johnsen NF, Hallund J, Tetens I (2004) A single measurement is inadequate to estimate enterolactone levels in danish postmenopausal women due to large intraindividual variation. J Nutr 134:1197–1200PubMed

56.

Bach Knudsen KE, Serena A, Kjaer AK et al (2003) Rye bread in the diet of pigs enhances the formation of enterolactone and increases its levels in plasma, urine and feces. J Nutr 133:1368–1375PubMed

57.

Souhami RL, Tannock I, Hohenberger P, Horiot J-C (2002) Oxford textbook of oncology. Oxford: Oxford University Press

58.

Sonnenberg A, Muller AD (1993) Constipation and cathartics as risk factors of colorectal cancer: a meta-analysis. Pharmacology 47(Suppl 1):224–233CrossRefPubMed

59.

Kirkman LM, Lampe JW, Campbell DR, Martini MC, Slavin JL (1995) Urinary lignan and isoflavonoid excretion in men and women consuming vegetable and soy diets. Nutr Cancer 24:1–12CrossRefPubMed

60.

Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon FE, Hughes AO (1992) Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 33:818–824CrossRefPubMed

61.

Probert CS, Emmett PM, Heaton KW (1995) Some determinants of whole-gut transit time: a population-based study. QJM 88:311–315PubMed

62.

Roberts MC, Millikan RC, Galanko JA, Martin C, Sandler RS (2003) Constipation, laxative use, and colon cancer in a North Carolina population. Am J Gastroenterol 98:857–864CrossRefPubMed

63.

Iacopetta B (2002) Are there two sides to colorectal cancer? Int J Cancer 101:403–408CrossRefPubMed

64.

Benassayag C, Perrot-Applanat M, Ferre F (2002) Phytoestrogens as modulators of steroid action in target cells. J Chromatogr B Analyt Technol Biomed Life Sci 777:233–248CrossRefPubMed

65.

Matthews J, Gustafsson JA (2003) Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 3:281–292CrossRefPubMed

Titel: Plasma enterolactone and risk of colon and rectal cancer in a case–cohort study of Danish men and women
verfasst von: Nina Føns Johnsen
Anja Olsen
Birthe Lykke Riegels Thomsen
Jane Christensen
Rikke Egeberg
Knud Erik Bach Knudsen
Steffen Loft
Kim Overvad
Anne Tjønneland
Publikationsdatum: 01.01.2010
Verlag: Springer Netherlands
Erschienen in: Cancer Causes & Control / Ausgabe 1/2010
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-009-9445-5

Neu im Fachgebiet Onkologie

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Plasma enterolactone and risk of colon and rectal cancer in a case–cohort study of Danish men and women

Abstract

Neu im Fachgebiet Onkologie

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Screening mammography intervals among postmenopausal hormone therapy users and nonusers

Reproductive factors, exogenous female hormone use and breast cancer risk in Japanese: the Miyagi Cohort Study

Low cancer incidence rates in Ohio Amish

The effects of polymorphisms in methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), and methionine synthase reductase (MTRR) on the risk of cervical intraepithelial neoplasia and cervical cancer in Korean women

Beliefs about the causes of breast and colorectal cancer among women in the general population

The association between fruit and vegetable consumption and HPV viral load in high-risk HPV-positive women with cervical intraepithelial neoplasia

Neu im Fachgebiet Onkologie

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Update Onkologie